Surrozen Reports Deepened Q1 Net Loss of $127.5M Amidst Patent Challenge, Secures $26.9M from ATM

summarizeSummary

Surrozen, Inc. reported a significantly increased net loss of $127.5 million for Q1 2026, primarily due to non-cash fair value adjustments, alongside a 34% rise in cash used in operations. The company also disclosed a patent challenge from Merck and continued to raise capital through its ATM program, securing $26.9 million.

check_boxKey Events

• Deepened Net Loss

  Q1 2026 net loss surged to $127.5 million, up from $27.0 million in Q1 2025, largely driven by non-cash fair value adjustments of tranche and warrant liabilities.

• Increased Cash Burn

  Cash used in operating activities rose to $12.5 million in Q1 2026, compared to $9.3 million in the prior year period.

• Patent Challenge from Merck

  Merck filed a post-grant review petition in February 2026 challenging a key patent (U.S. Patent No. 12,297,278) related to Surrozen's SWAP platform.

• Capital Infusion from ATM and Warrants

  The company raised $26.9 million in net proceeds from its 2025 ATM program and $3.3 million from warrant exercises during Q1 2026. An additional $0.8 million from warrant exercises was received in April 2026.

auto_awesomeAnalysis

Surrozen's Q1 2026 results highlight significant financial challenges, with a substantial net loss primarily stemming from non-cash fair value adjustments of complex financial instruments. The increase in cash used in operations indicates a higher burn rate, underscoring the company's ongoing need for capital. While the successful utilization of the ATM program and warrant exercises, along with the $5.0 million milestone payment from Boehringer Ingelheim, provide crucial liquidity, the new patent challenge from Merck introduces a material legal and intellectual property risk. The company's future liquidity is also contingent on the second tranche of the 2025 PIPE, tied to FDA clearance for SZN-8141 by October 2026. Investors should monitor the progress of the patent dispute and the SZN-8141 IND application, as these events will significantly impact the company's financial stability and long-term prospects.